Trastuzumab for patients with HER2 positive breast cancer: Delivery, duration and combination therapies

Breast

Volumn 22, Issue S2, 2013, Pages

  Pinto, Ana Catarina ^a   Ades, Felipe ^a   de Azambuja, Evandro ^a   Piccart Gebhart, Martine ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Adjuvant treatment; Chemotherapy; Early breast cancer; HER 2 positive; Intravenous trastuzumab; Subcutaneous trastuzumab

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; LAPATINIB; RECOMBINANT HYALURONIDASE; TAXANE DERIVATIVE; TRASTUZUMAB;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL PROTOCOL; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; DRUG COST; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; HEART DISEASE; HUMAN; INFLAMMATORY BREAST CANCER; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT SATISFACTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADJUVANT TREATMENT; CHEMOTHERAPY; EARLY BREAST CANCER; HER-2 POSITIVE; INTRAVENOUS TRASTUZUMAB; SUBCUTANEOUS TRASTUZUMAB;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84884724778     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.07.029     Document Type: Article

References (20)

1. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. The New England Journal of Medicine 2005 Oct 20, 353(16):1659-1672.
2. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer C.E., Davidson N.E., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. The New England Journal of Medicine 2005 Oct 20, 353(16):1673-1684.
3. Moja L., Tagliabue L., Balduzzi S., Parmelli E., Pistotti V., Guarneri V., et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database of Systematic Reviews (Online) 2012, 4. CD006243.
4. Goldhirsch A., Piccart M., Procter M., De Azambuja E., Weber H., Untch M., et al. HERA trial: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with her2-positive early breast cancer at 8 years of median follow up. Annals of Oncology 2012, 23(Suppl.9):ixe1-ixe30.
5. Goldhirsch A., Piccart M., Procter M., De Azambuja E., Weber H., Untch M., et al. HERA trial: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with her2-positive early breast cancer at 8 years of median follow up. Cancer Research December 15, 2012, 72(24 Suppl.).
6. Romond E., Suman V.J., Jeong J.-H., Sledge G.J., Geyer J.C., Martino S., et al. Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831. Cancer Research December 15, 2012, 72(24).
7. Pivot X., Romieu G., Bonnefoi H., Pierga J.Y., Kerbrat P., Guastalla J.P., et al. PHARE Trial results comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer. Annals of Oncology 02/10/2012, 23(Suppl.9):ixe1-ixe30.
8. Pivot X., Romieu G., Bonnefoi H., Pierga J.Y., Kerbrat P., Guastalla J.P., et al. PHARE trial results of subset analysis comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer. Cancer Research December 15, 2012, 72(24 Suppl.).
9. Perez E.A., Romond E.H., Suman V.J., Jeong J., Davidson N.E., Geyer C.E., Martino S., Mamounas E.P., Kauffman P.A., Wolmark N. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. Journal of Clinical Oncology 2007, ASCO Annual Meeting Proceedings Part I. 25, No. 18S (June 20 Supplement), 512.
10. Perez E.A., Romond E.H., Suman V.J., Jeong J.H., Davidson N.E., Geyer C.E., et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. Journal of Clinical Oncology 2011 Sep 1, 29(25):3366-3373.
11. Slamon D., Eiermann W., Robert N., Pienkowski T., Martin M., Press M., et al. Adjuvant trastuzumab in HER2-positive breast cancer. The New England Journal of Medicine 2011 Oct 6, 365(14):1273-1283.
12. Perez E.A., Suman V.J., Davidson N.E., Gralow J.R., Kaufman P.A., Visscher D.W., et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology 2011 Dec 1, 29(34):4491-4497.
13. Tomasello G., de Azambuja E., Dinh P., Snoj N., Piccart-Gebhart M. Jumping higher: is it still possible? The ALTTO trial challenge. Expert Review of Anticancer Therapy 2008 Dec, 8(12):1883-1890.
14. Joensuu H., Bono P., Kataja V., Alanko T., Kokko R., Asola R., et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial. Journal of Clinical Oncology 2009 Nov 2.
15. Gonzalez-Angulo A.M., Litton J.K., Broglio K.R., Meric-Bernstam F., Rakkhit R., Cardoso F., et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. Journal of Clinical Oncology 2009 Dec 1, 27(34):5700-5706.
16. Curigliano G., Viale G., Bagnardi V., Fumagalli L., Locatelli M., Rotmensz N., et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. Journal of Clinical Oncology 2009 Dec 1, 27(34):5693-5699.
17. Theriault R.L., Litton J.K., Mittendorf E.A., Chen H., Meric-Bernstam F., Chavez-Macgregor M., et al. Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype. Clinical Breast Cancer 2011 Oct, 11(5):325-331.
18. Joensuu H., Isola J., Lundin M., Salminen T., Holli K., Kataja V., et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clinical Cancer Research 2003 Mar, 9(3):923-930.
19. Goldhirsch A., Wood W.C., Coates A.S., Gelber R.D., Thurlimann B., Senn H.J. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Annals of Oncology 2011 Aug, 22(8):1736-1747.
20. Ismael G., Hegg R., Muehlbauer S., Heinzmann D., Lum B., Kim S.B., et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. The Lancet Oncology 2012 Sep, 13(9):869-878.